Genentech, a Roche Group member (RHHBY.OB), Thursday presented new findings at the AD/PD 2025 International Conference in Vienna, highlighting advancements in Alzheimer's and Parkinson's disease research.
The company shared Phase Ib/IIa data from its Brainshuttle AD study, showing that its investigational drug, trontinemab, led to rapid, dose-dependent amyloid plaque reduction in Alzheimer's patients. A Phase III trial for trontinemab is set to begin later this year.
Additionally, Roche's Elecsys pTau181 blood test demonstrated potential for ruling out amyloid pathology, aiming to simplify Alzheimer's diagnosis.
The Elecsys pTau181 test is expected to roll out in Europe by late 2025, followed by its launch in the U.S.
Now, turning to the company's Parkinson's research.
Roche revealed Phase IIb results from the PADOVA study on prasinezumab, which did not meet its primary endpoint but showed possible benefits in slowing motor progression. Further evaluation is ongoing.
RHHBY.OB is currently trading at $40.69 up $1.38 or 3.51 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.